Design considerations in long-term intervention studies for the prevention of cognitive decline or dementia

Nutrition Reviews

Volumn 68, Issue SUPPL. 1, 2010, Pages

  Dangour, Alan D ^a   Allen, Elizabeth ^a   Richards, Marcus ^b   Whitehouse, Peter ^c   Uauy, Ricardo ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Cognitive function; Dementia; Long term interventions; Recruitment; Study design

Indexed keywords

5,8,11,14,17 ICOSAPENTAENOIC ACID; DOCOSAHEXAENOIC ACID; FOLIC ACID; GINKGO BILOBA EXTRACT; PLACEBO; POLYUNSATURATED FATTY ACID;

ALZHEIMER DISEASE; ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; FOLLOW UP; GENETIC MARKER; HUMAN; INCIDENCE; MEMORY; NEUROPSYCHOLOGICAL TEST; NUTRITION; RISK BENEFIT ANALYSIS;

COGNITION DISORDERS; DEMENTIA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 77958467736     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2010.00330.x     Document Type: Article

References (22)

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112-2117.
2. Qaseem A, Snow V, Cross JT, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148:370-378.
3. Gillette Guyonnet S, Abellan Van Kan G, Andrieu S, et al. IANA task force on nutrition and cognitive decline with aging. J Nutr Health Aging. 2007;11:132-152.
4. Luchsinger JA, Mayeux R. Dietary factors and Alzheimer's disease. Lancet Neurol. 2004;3:579-587.
5. Hennekens CH, Demets D. The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. JAMA. 2009;302:2361-2362.
6. Luchsinger JA, Gustafson DR. Adiposity and Alzheimer's disease. Curr Opin Clin Nutr Metab Care. 2009;12:15-21.
7. Stewart R, Xue QL, Masaki K, et al. Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension. 2009;54:233-240.
8. Durga J, Van Boxtel MP, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet. 2007;369:208-216.
9. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300:2253-2262.
10. Dangour AD, Allen E, Elbourne D, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double blind, controlled trial. Am J Clin Nutr. 2010;91:1725-1732.
11. Dangour AD, Clemens F, Elbourne D, et al. A randomised controlled trial investigating the effect of n-3 long-chain polyunsaturated fatty acid supplementation on cognitive and retinal function in cognitively healthy older people: the Older People And n-3 Long-chain polyunsaturated fatty acids (OPAL) study protocol [ISRCTN72331636]. Nutr J. 2006;5:20.
12. Fitzpatrick AL, Fried LP, Williamson J, et al. Recruitment of the elderly into a pharmacologic prevention trial: the Ginkgo Evaluation of Memory Study experience. Contemp Clin Trials. 2006;27:541-553.
13. Cohen-Mansfield J. Recruitment rates in gerontological research: The situation for drug trials in dementia may be worse than previously reported. Alzheimer Dis Assoc Disord. 2002;16:279-282.
14. Office of National Statistics. Population Estimates for UK, England and Wales, Scotland and Northern Ireland. Office for National Statistics, 2008.
15. Marmot M, Banks J, Blundell R, Lessof C, Nazroo N. Health, Wealth and Lifestyles of the Older Population in England: The 2002 English Longitudinal Study Of Ageing. London: Institute for Fiscal Studies; 2003.
16. Craig R, Mindell J. Health Survey for England 2006. Vol. 1:Cardiovascular disease and risk factors in adults. London: The National Centre for Social Research; 2007.
17. DeKosky ST, Fitzpatrick A, Ives DG, et al. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials. 2006;27:238-253.
18. Durga J, Van Boxtel MP, Schouten EG, et al. What can we learn from the FACIT trial: a randomized, double blind, controlled trial. J Nutr Health Aging. 2007;11:320-324.
19. Whitehouse PJ. Mild cognitive impairment - a confused concept? Nat Clin Pract Neurol. 2007;3:62-63.
20. Gillette-Guyonnet S, Andrieu S, Dantoine T, Dartigues JF, Touchon J, Vellas B. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease. Alzheimers Dement. 2009;5:114-121.
21. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734-746.
22. Brinkley TE, Lovato JF, Arnold AM, et al. Effect of ginkgo biloba on blood pressure and incidence of hypertension in elderly men and women. Am J Hypertens. 2010;23:528-533.